P
oor adherence to antihypertensive treatment is likely to be a major contributor to treatment failure, which may result in more visits to healthcare professionals, unnecessary medication switches, dose escalations, and even hospitalization. 1 It is estimated that at least 50% of patients in a general hypertensive population do not take their antihypertensive medication as prescribed. 2 Therefore, improving adherence to prescribed drug regimens in this population remains a major challenge to the treating physician.
Over the last decades, several studies assessing adherence to antihypertensive drugs have used pillboxes that electronically record every opening. 3 Mean adherence rates in these studies ranged between 75% and 95% depending on the definitions used. 4 -11 A few studies have assessed the effect of the use of electronic monitors on BP. [12] [13] [14] Interestingly, even without treatment adjustment, electronic monitoring of adherence may lead to lower BP levels or even a normalization of BP in a substantial part of the patients, as illustrated in a study by Burnier et al. Comparable results were obtained by Waeber et al, 14 who found that diastolic BP normalized in 57% of patients after a 3-month monitoring period. These studies indicate that inadequate adherence may be responsible for a lack of response to the prescribed medication, at least in part of the hypertensive population, and that the problem can be managed to a certain degree by monitoring adherence. Unfortunately, both studies did not use control groups. This is important because the very fact that patients are being monitored under experimental conditions may already reduce BP, irrespective of changes in patient adherence to treatment regimens. Therefore we performed a pragmatic randomized controlled trial in which we compared an experimental strategy using electronic monitoring of adherence to usual clinical care in patients who had uncontrolled hypertension despite antihypertensive treatment. This design allows us to ascertain whether electronic monitoring in these patients is an effective alternative to routine clinical practice, which would imply increasing the intensity of pharmacologic treatment.
Methods

Study Population
Patients were recruited by 43 physicians in The Nether Patients were eligible if they met all of the following criteria: a) diagnosis of hypertension, b) inadequate BP control despite the use of antihypertensive drugs; and c) indication for treatment escalation. Patients were excluded if they changed therapy because of adverse effects of current medication, insisted on using dose organizers, were not managing their drug intake themselves, or were institutionalized. Treatment escalation was defined as increase in dosage of existing medication and/or addition of other antihypertensive drugs. Hypertension was defined 15 as a systolic BP (SBP) Ն160 mm Hg or diastolic BP (DBP) Ն95 mm Hg according to the national guideline of the family physicians that were in force at the start of the study. In the Dutch healthcare system all citizens are enlisted with a family physician. These family physicians function as gatekeepers to secondary care. All included patients gave written informed consent.
Study Design
In the first phase of the study, which lasted 2 months, patients were randomly assigned to either of two strategies: 1) continuation of usual care, with adjustment of antihypertensive medication if necessary; or 2) introduction of electronic monitoring and no medication changes.
Randomization was performed centrally through the Trial Coordinating Center by telephone. For each physician a random allocation scheme was generated by the study coordinator using computer-generated random permuted blocks with a block size of 6. The treating physician phoned the Trial Coordinating Center to randomize the patient to its treatment group. Within the first phase, adherence in patients who were assigned to electronic monitoring was monitored electronically for 2 months without medication changes. Patients in the monitoring group received, for each antihypertensive drug they used, a pillbox equipped with a microchip in its lid that registered the date and time of each opening (Medication Event Monitoring System (MEMS), Aardex Corporation, Geneva, Switzerland). The MEMS monitors were provided to the patients by their local pharmacists. Although neither the treating physician nor the pharmacist addressed issues of adherence with the participating patients, the patients were aware that the MEMS monitor recorded the date and time of each opening of the medication bottle. This information was mentioned in the patient information to meet the requirements of the medical ethics committee. Each opening was considered as being a single dose intake. After the 2-month monitoring period, adherence data were downloaded to a personal computer using dedicated software (PowerView version 2 software (Aardex Corporation) and the adherence data were discussed with the patients by way of providing feedback. Adherence was defined as the percentage of days with number of doses taken as prescribed (ie, correct dosing). Patients were arbitrarily considered to be compliant when the percentage of days with correct dosing was Ն85% for all prescribed antihypertensive medications. At the end of the first phase, patients from the monitoring group were referred to the treating physician. The physician was informed about BP and adherence and could then decide whether to increase the medication.
During the second phase of the trial, which lasted 3 months, patients from both experimental arms received usual care. This design allowed us to evaluate whether a short-term intervention with a monitor is sufficient to maintain the BP-lowering effect of monitoring over time.
The study was approved by the Medical Ethical Committee of Maastricht University.
Baseline and Follow-Up Measurements
Adherence Measurements In addition to the measurements by the electronic monitors, adherence based on pharmacy records was estimated for a period of 12 months before the start of electronic monitoring. Furthermore, to assess the occurrence of selection bias, we also determined refill adherence from 40 patients who chose not to participate in the trial.
Refill adherence during the interval between two prescription fills was calculated as the number of days for which pills were prescribed divided by the total number of days in this interval. Mean percentage refill adherence for the period of 12 months preceding the trial was computed by adding the percentages of each interval and dividing the sum by the number of intervals. As is the case with correct dosing, satisfactory refill adherence was defined as an average refill adherence Ն85%.
Measurement of BP
At inclusion, office BP was measured by the physician using conventional sphygmomanometry. Further BP measurements were carried out at the end of the first and second phase of the trial (2 and 5 months after inclusion). To avoid assessment bias caused by the fact that the treating physician was aware of the treatment allocation, all of these measurements (2 and 5 months) were performed by a research nurse using the Omron 705 CP automated BP monitor with printed output. At each follow-up visit, BP was measured three times with the patient in a sitting position after 5 min of rest. Mean SBP and DBP were used for analysis.
Statistical Analysis
We applied a randomization ratio of electronic monitoring versus usual care of 2:1. This asymmetric allocation schema was chosen to provide a reliable estimate of the percentage nonadherence in the electronic monitoring group. It was assumed that normalization of BP would occur in 50% of the patients in the usual care group. To reject the hypothesis of a difference in proportions with normalized BP of Ն20% with a significance level of 5% (two-sided) and a power of 85%, 164 and 89 patients were needed in the monitoring and usual care group, respectively. With this sample size, the power to demonstrate with 95% confidence (two-sided) a difference of Ն15% is a power of 60%.
Relevant baseline characteristics were collected to assess the comparability of the randomized groups.
Results were analyzed according to an intention-to-treat analysis. The primary outcome measure was the proportion of patients with normalized BP (SBP Ͻ160 mm Hg and DBP Ͻ95 mm Hg) at 5 months after inclusion. Secondary endpoints were a) the proportion of patients with non-normalized but improved BP (SBP reduction Ն10 mm Hg and DBP reduction Ն5 mm Hg); b) the mean reduction in systolic and diastolic BP as compared with the BP that was measured by the physician at inclusion; and c) the proportion of patients with escalation of medication. Differences between proportions were tested using the 2 test, differences between means were tested by the unpaired Student t test (␣ ϭ 0.05).
Logistic multivariate regression models were used to adjust for small imbalances in baseline characteristics between groups.
Results
Patients
Between September 2002 and March 2004, a total of 258 patients were recruited. Two of them were lost to follow-up, as they refused further participation because of illness. One patient died of stroke and two patients refused further cooperation after inclusion without giving specific reasons. Therefore, complete outcome measures were available for 253 patients (98%), 164 patients in the electronic monitoring group and 89 patients in the usual care group (Fig. 1) . Patient characteristics are shown in Table 1 . Percentages of patients with satisfactory adherence based on pharmacy data were comparable in both groups (81% v 77% in the electronic monitoring and usual care group, respectively). The percentage of patients with adequate adherence in a random sample of patients that did not participate in the study was 87%.
First Phase At the end of the first phase of the trial, at 2 months after inclusion, 38.6% of patients in the electronic monitoring group v 57.8% in the usual care group reached adequate BP control (P Ͻ .01).
After 2 months of monitoring, average adherence, expressed as percentage of days with correct dosing, was 95.3% Ϯ 10% in the electronic monitoring group. The percentage of correct dosing was Ն85% in 95.8% of the patients randomized to the electronic monitoring group. Monitoring adherence was better than refill adherence as determined before inclusion. Refill adherence, also with a cut-off point of Ն85%, showed that adherence was satisfactory in only 81% of these patients (Table 1) .
Immediately upon monitoring, patients from the experimental group were referred to their physician. Medication was escalated (drug additions or dose escalations or both) in 47.6% of the patients with no improvement in BP in comparison with 16.3% in the patients with improved or normalized BP in the electronic monitoring group. Assessed for eligibility * (n=319) * Adequate assessment for eligibility was feasible in only 9 general practices.
FIG. 1. Flow of participants through the study.
Second Phase Although there were clear differences in BP control between the usual care and electronic monitoring group at 2 months, this difference disappeared at 5 months. At 5 months after inclusion, 50.6% of the patients in the usual care group reached adequate BP control v 53.7% in the electronic monitoring group (P ϭ .73). In addition, BP had not normalized but substantially decreased in 11.2% v 16.5% of the patients (P ϭ .35). Average BP reductions were similar (10 mm Hg for DBP and 15 mm Hg for SBP in both groups, respectively) ( Table 2 ). The percentages of drug additions and/or dose escalations were higher in the usual care group compared with the electronic monitoring group (P Ͻ .01). Initially, in the usual care group, medication was changed in 72.3% of the patients shortly after enrollment. In 12.2% of the patients in the usual care group, medication was readjusted again resulting in a net result of no change at 5 months. Eventually, the net percentage of patients with a dose increase or drug addition or both was 61.1% in the usual care group (Table 3 ). In the monitoring group, at 5 months the medication had been changed in 33.5% and readjusted in 4.6%, resulting in a net increase in 28.9% of the patients. The difference in proportions between the groups with a net change in medication (Ϫ32.2%) was statistically significant (P Ͻ .01) ( Table 3) . Table 1 showed that there were small imbalances in baseline characteristics between groups. None of the differences were statistically significant, but we incorporated baseline variables with a difference exceeding 3% in a multivariate logistic model to check whether the small differences affected the result. This was not the case. Monitoring was associated with an odds ratio of 1.12 (95% CI ϭ 0.67 to 1.88) for normalization at 5 months before adjustment, and an odds ratio of 1.11 (95% CI ϭ 0.59 to 2.08) after adjustment (for age (Յ65 v Ͼ65), gender, cholesterol Ն5 mmol/L, diabetes mellitus, myocardial infarction, peripheral arterial disease, and number of antihypertensive tablets per day (Յ2 v Ͼ2).
Discussion
An important observation in our study was that electronic monitoring of adherence resulted in a normalization of BP in 53.7% of the patients, whereas the need for treatment escalations was strongly reduced. These data support the assumption that poor adherence is a common cause of treatment resistant hypertension, and provide evidence that in many patients persisting hypertension has its origin in poor adherence. 16 An obvious explanation for our findings is that patients were aware of the fact that they were being monitored, because this was explained to them in the patient information. This probably encouraged them to be more compliant with treatment than they had been before. This assumption also explains the low prevalence of poor adherence during electronic monitoring, whereas, based on pharmacy records, the prevalence of poor adherence before the start of the study was 19% in the electronic monitoring group.
An important question when applying electronic monitoring in clinical practice is whether a short-term intervention with a monitor is sufficient to maintain the Data are mean scores Ϯ SD and proportions (n).
* As measured by the general practitioner at the office, all other BP measurements are performed by the research nurse at the patient s home. * Differences in proportions between the groups: P Ͻ 0.01. † Includes both patients with no medication change during the follow up period and patients with an initial increase in medication followed by a decrease resulting in a net change of zero.
BP-lowering effect of monitoring over time. From our results it can be concluded that a relatively short monitoring period is sufficient to sustain BP reductions for at least 5 months. It is possible that these results reflect a patient's learning process in which daily medication intake eventually becomes incorporated as a habit.
The results of this study are in agreement with other studies that also point in this direction. 4, 7, 9, 17 In contrast with the general assumption that adherence is inadequate in about 40% to 50% of patients, 2 recent studies using electronic monitoring often report lower proportions of patients with poor adherence. 4, 7, 9, 17 This discrepancy suggests that electronic monitoring itself improves adherence. More direct evidence comes from studies of Burnier et al 12 and Waeber et al, 14 who demonstrated that a 2-or 3-month period of monitoring of adherence was associated with a significant improvement of BP.
According to recent reviews most interventions are complex, labor intensive, and not predictably effective. 18, 19 Electronic monitoring would be an easy-to-use intervention in contrast to other interventions that have been evaluated in randomized controlled trials.
Certain methodologic issues in the present study deserve attention. Patients were informed about the study and they gave written consent to participate in the study. Theoretically this could lead to a selection of patients who have fewer problems with taking their medication as prescribed. Such a selection could explain the overall high percentage of adherence as measured by electronic monitoring. Therefore, refill adherence from all participants was compared with that of 40 patients that chose not to participate in the study. In 13% of the patients who did not participate adherence was poor, compared with 20% in the group of participants. This finding indicates that patients with adherence problems, as defined by refill adherence, were more inclined to participate, making selection bias toward patients with good adherence less likely.
Baseline BP measurements were office based and made by the physician, whereas BP measurements at the end of the first phase and second phase were performed by the research nurse using the Omron 705 CP automated BP monitor. Part of the decrease in BP in both groups might be explained by different measurement methods during inclusion and follow-up (measurement bias). However, given the fact that the effectiveness of antihypertensive medication is well accepted, the decrease in BP in the usual care group cannot be explained by measurement bias alone. Likewise, it can be expected that part of the decrease in BP in the electronic monitoring group can be attributed to electronic monitoring.
According to the protocol, medication should have been increased in all patients who were assigned to the usual care strategy. However, in the usual care group, medication was not changed in 27.7% of the patients. A common reason for this was that the treating physician preferred to await the effects of lifestyle changes on BP. It can be argued that the fact that medication was not changed in some patients resulted in underestimation of the 5-month BP reductions that can be achieved by medication change. However, lack of adjustment also occurred in the electronic monitoring group in those patients who, after monitoring, still had high BP (40 of 84 patients). Assuming that these patients had an indication for medication adjustment, nonadherence to the national guidelines occurred in a proportion similar to that in the usual care group, namely in 24.4% (40/164) of patients. Therefore, it is unlikely that the similar effectiveness in both strategies can be attributed to differences in protocol deviations between the groups.
Implementation of electronic monitoring in general practice could be recommended in situations in which patients do not reach BP targets and both patient and physician are reluctant to increase the dose or number of antihypertensive drugs. In consensus with the patient, it is possible to explore whether dosing errors may be a cause of inadequate response to antihypertensive medication. Thus, in the group of patients with adherence problems, the use of an electronic monitor can offer an escape from further escalation of antihypertensive medication or further diagnostic work-up.
To our knowledge, this is the first randomized study on the effect of electronic monitoring on BP regulation. Further randomized trials with longer follow-up are needed to confirm the effectiveness of this approach and to evaluate whether BP control can be sustained over a longer period of time.
We conclude that electronic monitoring that electronic monitoring in comparison to usual care results in similar BP control but leads to less drug changes and drug use. This result is likely to be achieved through improving adherence. According to these results, electronic monitoring expands the therapeutic possibilities to treat hypertension.
